J·TEC

FY2027 Q1 Financial Results Briefing Materials

再生医療をあたりまえの医療に

Creating a Future for Regenerative Medicine

Japan Tissue Engineering Co., Ltd. (TSE Growth: 7774)

July 30, 2026

FY2027 Q1 Results Summary

Q1 achieved significant revenue growth and profitability driven by JACC for OA, making progress toward building a stable profitable base.

FY2027 Q1 Results

Net Sales	766	
	YoY	+340
Operating Profit	59	
	YoY	+303
Net Income	52	
	YoY	+294

(Millions of yen)

Profitability Achieved Driven by JACC Sales Growth

JACC Orders Received

Annual Target **350 cases**

111 cases in Q1



- JACC Orders Received: **111** cases in Q1.
- Including orders from Q2 onwards, the total for this fiscal year is **220** cases.※
- Contracts completed with **143** facilities.※

※：As of July 29, 2026

FY2027 Q1 Financial Results

- ✓ Achieved revenue growth in all businesses except Teijin CDMO.
- ✓ Significant revenue increase in JACC drove profitability.

Unit：Millions of Yen (rounded down to the nearest million yen) (percentage changes calculated based on yen units)	FY2025	FY2026			
	Q1 Actual	Q1 Actual	YoY Change		Year Forecast Disclosed May 1, 2026
			Amount	Percent	
Regenerative Medicine Product Sales	**262**	**603**	**340**	**130%**	**2,070**
Dermatology（JACE、JACEMIN）	162	316	153	94%	1,070
Cartilage（JACC）	78	255	✓ 177	226%	900
Cornea（NEPIC、OCURAL）	21	30	9	47%	100
Regenerative Medicine Contract Sales	**100**	**94**	**△5**	**△5%**	**640**
General Contracts	45	87	41	90%	430
Teijin Contracts	54	7	△46	△85%	210
LabCyte Business Sales	**63**	**68**	**5**	**8%**	**360**
Total Sales	**426**	**766**	**340**	**80%**	**3,070**
Gross Profit	**216**	**512**	**296**	**137%**	**2,000**
SG＆A	**460**	**453**	**△7**	**△2%**	**1,900**
Operating Profit	**△244**	✓ **59**	**303**	**-**	**100**
Ordinary Profit	**△241**	**63**	**304**	**-**	**110**
Net Income	**△242**	**52**	**294**	**-**	**100**

Overview of FY2027 Q1 Results

External Factors	✓For JACE, the number of target burn cases, which dropped in the previous year, **has recovered**. ✓Teijin CDMO saw a decrease in revenue due to the completion of know-how provision.
Internal Factors	✓For JACC, **orders increased significantly following the expansion of the OA indication. Facility expansion is also progressing smoothly** (111 cases acquired in Q1, contracts completed with 143 facilities.※). ✓For JASMINE, **facility expansion and patient awareness initiatives were successful, leading to increased orders.** ✓The CDMO business saw revenue growth **due to the progression of customers' development phases**.

※：As of July 29, 2026

Operating Profit Trend（Quarterly）



Change in Operating Profit（Year-on-Year）



Progress on Growth Strategies: Regenerative Medical Products Business

Expansion of JACC usage facilities through sales partnerships

J-TEC × OSferion Biomaterials

- OA patients require a comprehensive treatment approach combining "cartilage repair" and "osteotomy※1," which corrects joint misalignment and reduces mechanical stress.
- Approximately 13,500※2 osteotomy procedures are performed annually. In addition, 60%※3 of JACC procedures for osteoarthritis are performed in combination with osteotomy.
- By partnering with OsferionBiomaterials Corp., which holds the top domestic market share in artificial bone and bone grafting materials for osteotomies, we aim to expand facilities using the "cartilage repair + osteotomy" treatment and strengthen our proposal capabilities.
- We aim to further accelerate the momentum of JACC orders from Q1 and establish a solid foundation for achieving 1,000 annual cases in the coming years through the promotion of knee joint preservation therapy.

Accelerating clinic-hospital collaboration for JACEMIN and creating a patient referral system



- Against an annual target of 50 orders, Q1 achieved 9 cases, and the current fiscal year total has progressed to 26 cases※4.
- Strengthening clinic-hospital collaboration (creating a patient referral system) with 52 facilities※3 nationwide that have established treatment systems.
- In addition, promoting the horizontal rollout of treatment track records from top facilities and patient awareness activities.

※1: A surgical procedure that relieves pain by correcting bone alignment and redistributing load through osteotomy, while preserving the patient's own joint.
※2: Source: National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), Ministry of Health, Labour and Welfare, FY2024.
※3: As of July 29, 2026
※4: Total for this fiscal year: Figures as of July 29, 2026, including orders from Q2 onwards.

Progress on Growth Strategies: Regenerative Medicine CDMO Business / LabCyte Business

Strengthening the CDMO Business Portfolio

METCELA

Autologous cell therapy product "JRM-001" for functional single ventricle.

AlliedCel

Induced regulatory T cells "JB-101" for suppressing immune rejection in organ transplant treatments.

ActualEyes

Regenerative medical cell product "AE101" for bullous keratopathy.

CELL THERAPY

Product "MastCT-03" using iPS cells for retinal degenerative diseases.

- In addition **to diversifying the customer base, development pipelines progressed to high-value-added phases**, contributing to revenue growth.
- **Strengthening our unique value proposition as an "Innovation Partner"** more than ever before.

Establishment of a German Subsidiary for the LabCyte Business Manufacturing Base

Manufacturing Base

Company Name:

Japan Tissue Engineering Europe GmbH

Location: Heidelberg, Germany

Business Description: Development, manufacturing, and sales of LabCyte products

Start of Operations: During the second half of FY2026

- **Decided to establish a manufacturing subsidiary in** Germany to overcome barriers such as the short shelf life of living cells and transportation risks.
- Partnering with fully equipped local shared labs to **quickly establish a robust local production and stable supply system**.
- **Aiming to expand market share** in Europe, an advanced market for alternative methods to animal testing.

Progress on Growth Strategies: New Pipeline Area

Area	Product Name	Indication	Target Launch	Basic Research	Preclinical Trials	Clinical Trials	Regulatory Approval	Insurance Listing
Skin	Allo-JaCE03	Skin defects including burns	FY2027				○ Approval application completed in Mar 2026	
Cancer	JPCAR019	Acute lymphoblastic leukemia	TBD			○ Phase I/II investigator-initiated clinical trial ongoing, with completion of the Phase I portion expected in FY2026.		

Medical Device

Dry allogeneic cultured epidermis　Allo-JaCE03

A new product made from allogeneic cells that can be mass-produced and stocked.
Aiming for a wider range of indications than JACE.

▶ Progressing smoothly toward approval during the current fiscal year.

Autologous CAR-T cells　JPCAR019



Non-viral vectors reduce manufacturing costs.
Expanding treatment options for patients who are not eligible for existing treatments.

▶ Progressing smoothly toward transition to the Phase II portion during the current fiscal year.
Commenced evaluation of business expansion into non-cancer indications.

New Exploration：Started establishing basic technology for "hair follicle organoids" as a new technology exploration for alopecia.

▶ Selected for the "New Aichi Creative Research and Development Subsidy".

Regenerative Medicine Products Business: Performance Overview

Dermatology

JACE

Recovered from the decrease in target severe burn patients in the previous year, with strong orders in Q1.
We will steadily contribute to saving lives in severe burn treatment.

JACEMIN

Q1 orders were **9 cases**; including orders from Q2 onwards, **the total for this fiscal year has progressed to 26 cases**. ※1
Strengthening clinic-hospital collaboration with 52 facilities nationwide that have established treatment systems, **while promoting the horizontal rollout of treatment track records from top facilities and patient awareness activities**.

※1：As of July 29, 2026

Sales Trend (million yen)



Cartilage

JACC



Q1 orders were **111 cases**; including orders from Q2 onwards, **the total for this fiscal year has progressed to 220 cases**. ※1
By focusing on carefully selected targets and increasing expectations for JACC in OA knee treatment, the number of user facilities has steadily expanded. We will promote further treatment penetration through collaboration with OsferionBiomaterials Corp., etc.

※1：As of July 29, 2026



Cornea

NEPIC OCURAL

The decline in target cases at existing facilities has bottomed out, and **increasing orders from new facilities have driven growth**.
Product evaluations from medical institutions remain favorable. We will continue promotional activities with NIDEK CO., LTD.



CDMO Business & LabCyte Business : Performance Overview

J-TEC

CDMO

General

Multiple projects transitioned to the high-value-added "clinical trial product manufacturing phase", contributing to revenue growth.

■ ActualEyes Inc.	Preparation for domestic Phase III clinical trials started.
■ VC Cell Therapy Inc.	Continued CDMO services toward the commercialization of iPS-derived products.
■ Metcela Inc.	Concluded a clinical trial product manufacturing contract, and manufacturing is progressing.
■ AlliedCel Corp.	Concluded a contract with a view to post-launch manufacturing, and commenced CDMO services.

Sales Trend (million yen)



Teijin

CDMO revenue decreased as know-how provision completed a cycle.
Planned on the assumption that milestones will be recorded in Q4.

LabCyte

Europe

Decided to establish a subsidiary in Germany for full-scale deployment via local production, moving forward toward starting production and expanding sales in the second half of the year.
Providing careful follow-up to 8 regular customers, while new customer acquisition activities are also progressing smoothly.

Japan

Fully commencing approaches to the medical device and materials markets, shifting from the previous cosmetics and chemical products-centric markets.



New Initiatives

Development is progressing toward the launch of an intestinal epithelium model for research use during the second half of the year.

FY2027 Q1 Financial Statements Supplementary Information

Operating Profit/Loss by Segment

Regenerative Medical Products Business drives profitability

Unit: million yen (Amounts rounded down to the nearest million yen)	Operating Profit/Loss			Factors
	FY2025 Q1 Actual	FY2026 Q1 Actual	Change Amount	
Product Business	△35	240	205	Significant revenue increase from JACC for OA
Contract Business	50	45	△5	In-house cultivation is strong, but know-how provision for Teijin CDMO has completed a cycle
LabCyte Business	18	14	△4	Strategic investments for overseas expansion
Adjustments	△277	△241	36	Promotion of Efficiency
Total	△244	59	303	

Balance Sheet

Strong cash and net assets, maintaining a healthy financial position

Unit: million yen (Amounts rounded down to the nearest million yen)	March 31, 2026	June 30, 2026	Change Amount
Cash and Deposits	3,250	3,347	96
Other Current Assets	931	1,078	146
Non-current and Deferred Assets	1,500	1,483	△17
Total Assets	5,682	5,908	225
Current Liabilities	560	733	173
Non-current Liabilities	32	32	-
Total Liabilities	592	766	173
Share Capital	3,997	3,997	-
Capital Surplus	1,827	1,827	-
Retained Earnings	△734	△682	52
Net Assets	5,090	5,142	52
Total Liabilities & Net Assets	5,682	5,908	225

Handling of This Document

This document is provided for informational purposes only and includes forward-looking business plans. It is not intended as an investment solicitation. Any evaluation of our plans or investment decisions should be made at the investor's own discretion.

The Company does not guarantee the achievement or realization of any business targets or projections and assumes no responsibility for them.

All forward-looking statements in this document are based on information available at the time and our current assumptions. Actual results may differ significantly due to changes in economic conditions or other factors affecting the underlying assumptions

.

Japan Tissue Engineering Co., Ltd.

〒443-0022 6-209-1Miyakita-dori, Gamagori City, Aichi Prefecture

TEL: 0533-66-2020 FAX: 0533-66-2019

Email: jtec-info@jpte.co.jp

Reference Materials

Excerpted from “Business Plan and Growth Potential,” disclosed on May 1, 2026.

Glossary of Our Products

Regenerative Medicine Products Business

We provide products cultured from the patient's own cells under insurance coverage.

NEPIC / OCURAL

Autologous Cultured Corneal Epithelium
Autologous Cultured Oral Mucosal Epithelium

■ Limbal Stem Cell Deficiency（LSCD）

JACE

Autologous Cultured Epidermis

■Severe burns ■Epidermolysis bullosa
■Giant congenital melanocytic nevus

JACEMIN

Autologous Cultured Epidermis Containing Melanocytes

■Vitiligo vulgaris.

JACC

Autologous Cultured Cartilage

■ Osteoarthritis of the knee（OA） ■ Traumatic cartilage defect / Osteochondritis dissecans



LabCyte Business

We sell kits to verify the safety of products like cosmetics and drugs using human cells as an alternative to animal testing

LabCyte

Human Cultured Tissue for Research

■Epidermis models
■Corneal epithelium models



EpiSensA

Skin Sensitization Test Method to evaluate the potential for substances to cause skin allergies, compliant with OECD guidelines

Our History

Leveraging a quarter century of experience in launching five products, we have established a unique platform for autologous cell therapies, distinct from traditional pharmaceuticals

Company Name	Japan Tissue Engineering Co., Ltd. (J-TEC)
Headquarters	Gamagori City, Aichi Prefecture
Representative Director	President and CEO: Kazuto Yamada
Established	February 1st, 1999
Share Capital	3,997,670,000 yen
Employees	200（As of March 31, 2026）
Business Areas	1. Regenerative Medicine Product Business 2. Regenerative Medicine Contract Business 3. LabCyte Business
Major Shareholders	Teijin Limited（57.7%） NIDEK Co., Ltd.（10.4%）

- 1999 Established
- 2007 Listed on JASDAQ Securities Exchange NEO (Currently Tokyo Stock Exchange Growth Market)
- 2009 Insurance Approval for JACE (severe burns)
- 2013 Insurance Approval for JACC (traumatic indications)
- 2016 Insurance Approval for JACE (Nevi)
- 2019 Insurance Approval for JACE (Epidermolysis Bullosa)
- 2020 Insurance Approval for NEPIC
- 2021 Insurance Approval for OCURAL
- 2024 Insurance Approval for JACEMIN
- 2026 Insurance Approval for JACC (Knee Osteoarthritis)

Social Implementation Phase

Our Growth Foundation

As Japan's first regenerative medicine platform company, we strive to establish a stable revenue foundation and drive rapid growth

【Achievements】Japan's first Regenerative Medicine Platformer

Founded in 1999, leading Japan's regenerative medicine industry for over 25 years.

5

5 products approved-Global track record

3,700+

3,700+ patients treated and a strong physician network

【Foundation】Strong Three-Pillar Business Model

Source of manufacturing and expertise



Advancing animal testing alternatives through global expansion of human cultured tissues

Expert support backed by launch experience

【Growth】Growth drivers for reaching ¥5B in revenue

Reimbursed JACC for knee osteoarthritis (target: ¥3B revenue)

Completed regulatory filing for manufacturing and marketing approval of dried allogeneic cultured epidermis Allo-JaCE03

Regenerative Medicine Product Business: Market Potential of "JACC"

Competitive Advantage

- ✓ A **unique, potentially curative approach distinct from conservative therapy** (exercise/drugs) and joint replacement
  #Cartilage has very limited natural healing once damaged
- ✓ **No products with the same mechanism currently**
- ✓ 10+ years of real-world use data
- ✓ **Proven efficacy and safety** from clinical trials



Pre-transplant | 6 months post-transplant | 1 Year post-transplant

Clinical trial results: 97.4% showed repair

Market Potential

- ✓ Target common diseases to boost awareness of regenerative medicine through insurance coverage

Symptomatic OA	Approx. 10M	
Eligible Population	Approx. 10K cases/year	*Estimated based on surgical volume and product indication criteria
Initial Target	Approx. 1,000 cases/ year	

Insurance coverage criteria for "JACC"

Patients diagnosed with OA

Not improved with conservative therapy (exercise/medication)

Cartilage defect area ≥ 2 cm^2 * And a sufficient amount of normal cartilage remains

Regenerative Medicine Product Business: Product Lineup

Product	Autologous Cultured Epidermis ジェイス® 自家培養表皮  Japan's First Regenerative Medicine Product	Autologous Cultured Cartilage ジャック® 自家培養軟骨  Japan's 2nd Regenerative medicine product	Autologous Cultured Corneal Epithelium ネピック® 自家培養角膜上皮  First Regenerative Medicine Product in Japan for Corneal Field	Autologous Cultured Oral Mucosal Epithelium オキュラル® 自家培養口腔粘膜上皮  2nd Regenerative Medicine Product in Japan for Corneal Field	Autologous Cultured Epidermis Containing Melanocytes ジャスミン メラノサイト含有自家培養表皮  Regenerative Medicine Product for Vitiligo
Approval Insurance	Oct. 2007 Jan. 2009	①Jul. 2012 ②May 2025 ①Apr. 2013 ②Jan. 2026	Mar. 2020 Jun. 2020	Jun. 2021 Dec. 2021	Mar. 2023 Oct. 2024
Indications	①Severe Burns ②Congenital giant pigmented nevus ③Epidermolysis bullosa	① Cartilage defects or osteochondritis of the knee ② Osteoarthritis	Limbal stem cell deficiency	Limbal stem cell deficiency	Intractable Vitiligo unresponsive to non-surgical treatment
Insurance Price	Harvesting/Culturing kit 4,460,000 yen Processing/Transplant kit 154,000 yen / per sheet	Harvesting/Culturing kit 1,000,000 yen Processing/Transplant kit 1,890,000 yen	Harvesting/Culturing kit 4,280,000 yen Processing/Transplant kit 5,470,000 yen	Harvesting/Culturing kit 4,280,000 yen Processing/Transplant kit 5,470,000 yen	Harvesting/Culturing kit 4,460,000 yen Processing/Transplant kit 154,000 yen / per sheet
Technology Origin	Harvard University Professor Howard Green	Hiroshima University Professor Mitsuo Ochi	University of Modena Professor G Pellegrini Professor M De Luca	Osaka University Professor Koji Nishida	University of Modena Professor G Pellegrini Professor M De Luca

Regenerative Medicine Contract Business Model

✓ As an innovation partner in regenerative medicine, we support end-to-end product development from customer seeds.

Value built by J-TEC

Development Expertise　　Regulatory Capability

Track Record in Commercialization and manufacturing

Network and Trust　　Full range of in-house functions

✖ Customer Relations

✖ Clinical settings Collaboration

✖ TEIJIN Collaboration

Building systems to deliver products together with partners

Commissioned projects 296 cases

Items	cases
Product development support Tech transfer, test cultures, preclinical studies, analytical validation, and SOP/document preparation	121
Regulatory affairs support PMDA consultations (pre-meetings & formal advice) and compliance with the Act on Safety of Regenerative Medicine, etc	30
Manufacturing & Testing support Investigational products and cell-processed materials	42
Clinical development support Protocol outlines, statistical analysis, data management, and clinical study reports	28
Facility & equipment support Consulting on the design and operation of manufacturing facilities	7
Others Sales support, equipment setup, and cell storage	68

LabCyte Business Model

- ✓ Advanced culture tech applied to offer “LabCyte Series” human tissues for research
- ✓ 3D human tissues for topical drugs, cosmetics, and skin/cornea research

Product Delivery Process

Cell Seller → Purchase of cells → J-TEC: Master cell bank construction and production of research-use cultured human tissues

Product Supply ↓ / Orders ↑

Manufacturers and research institutions handling chemicals (e.g., pharma, cosmetics, chemical products)

Use LabCyte for R&D

~~Animal Testing~~

	LabCyte EPI-MODEL	LabCyte EPI-KIT	LabCyte Corneal Model
Product	3D Cultured Human Epidermis	Epidermis Model Kit	3D Cultured human corneal Epithelium
			
OECD Test Guidelines	Skin irritation test (TG439) Skin Corrosion test (TG431) Skin Sensitization test (TG442D)	–	Eye Irritation test (TG492)
ISO (Medical Devices)	Skin Irritation test (ISO10993-23)		–
Launch Date	March 2005	April 2013	July 2010

Autologous Cultured Epidermis “JACE”



Indications	① Severe Burns Indicated for burns where deep second- and third-degree areas **total ≥30% total body surface area (TBSA)** ② Congenital Giant Pigmented Nevus Indicated for nevi ≥**5% TBSA** or when standard treatments cannot adequately remove the lesion ③ Epidermolysis bullosa dystrophica and junctional epidermolysis bullosa Indicated for erosions/ulcers persisting **~4 weeks or recurrent ulceration** with repeated epithelialization
Insurance reimbursement price	・Harvesting/Culturing kit: 4,460,000 yen ・Processing/Transplant kit: 154,000 yen per sheet ※ Eligible for high-cost medical expense coverage Limits:（Severe burns）**40sheets** ※if medically necessary, up to **50sheets** （nevi）**30sheets** （epidermolysis bullosa）**50sheets**
Technology	Originated from Professor Howard Green of Harvard University
Facility Standards	Severe burns: limited to facilities meeting required standards; not applicable to giant congenital nevi or epidermolysis bullosa
Healing timeline	Manufacturing and culture period: approximately 3 weeks from tissue collection to delivery Product shelf life: 56 hours Engraftment period: engraftment occurs within 1 week, with the epidermis stabilizing in approximately 1 month
Process	

Autologous Cultured Epidermis Containing Melanocytes “JACEMIN”

Indications	① Vitiligo* ・Vitiligo patients ≥12 years old unresponsive to or unsuitable for topical or light therapy. ・**Symptoms remain stable (unchanged) for about 12 months**
Insurance reimbursement price	・Harvesting/Culturing Kit: 4,460,000 yen ・Cultured Epidermis Package: 154,000 yen per sheet ※ Covered by the High-Cost Medical Expense Benefit system; out-of-pocket cost for an average-income person is about ¥220,000 (varies by income)
Technology	Originated from Professors G Pellegrini and M De Luca of the University of Modena (Italy)
Facility Standards	A full-time physician with experience performing **at least three skin graft procedures**, or a full-time physician who performs such surgeries under the supervision of an experienced doctor
Healing timeline	**Manufacturing & culture period:** About 5 weeks from tissue collection to delivery **Product shelf life:** 60 hours **Engraftment period:** Takes in about 1 week; epidermis stabilizes in ~1 month
Process	

* Complete depigmented patches due to vitiligo, Vogt–Koyanagi–Harada disease, chemical causes or congenital conditions such as piebaldism

Autologous Cultured Cartilage “JACC”



Indications	①Traumatic cartilage defect or osteochondritis dissecans. However, it is limited to cases where no other treatment options are available, and the cartilage defect area is 4cm² or larger. ②Osteoarthritis of the knee However, this is limited to cases where clinical symptoms do not improve through conservative treatments such as exercise therapy, and cartilage defect area is 2cm² or larger
Insurance reimbursement price	・Harvesting/Culturing Kit: 1,000,000 yen ・Processing/Transplant Kit: 1,890,000 yen number used not limited ※ Covered by the High-Cost Medical Expense Benefit system; out-of-pocket cost for an average-income person is about ¥250,000 (varies by income)
Technology	Originated from Professor Mitsuo Ochi of Hiroshima University
Facility Standards	A university hospital or other teaching/research institution, or a facility that performs at least 100 knee surgeries per year
Healing timeline	**Manufacturing & culture period:** About 4 weeks from cartilage tissue harvest to delivery **Product shelf life:** 80 hours **Engraftment period:** Use crutches or a brace (non-weight-bearing) for about 4 weeks post-op until the repair tissue stabilizes
Process	

Autologous Cultured Corneal Epithelium “NEPIC”
Autologous Cultured Oral Mucosal Epithelium “OCURAL”

Seller: NIDEK Co., Ltd.

Indications	Limbal Stem Cell Deficiency (LSCD)*
Insurance reimbursement price	・Harvesting/Culturing Kit: 4,280,000 yen ・Cultured Corneal Epithelium Package: 5,470,000 yen ※ Eligible for high-cost medical expense coverage
Technology	NEPIC Originated from Professors G Pellegrini and M De Luca of the University of Modena (Italy) OCURAL Originated from Professor Koji Nishida of Osaka University
Facility Standards	The facility must have a full-time physician with experience performing corneal transplantation
Healing timeline	**Manufacturing & culture period:** About 4 weeks from tissue collection to delivery **Product shelf life:** 60 hours **Engraftment period:** Takes in about 12 weeks; ocular surface stabilizes in 6–12 months
Process	Patients ← Transplantation NEPIC Harvesting of corneal limbal tissue → Enzymatic treatment → Seeding onto feeder cells for cell expansion → Isolation of cells → Culturing → Sheet formation → Sheet detachment OCURAL Harvesting of oral mucosal tissue



*Candidates for NEPIC exclude patients with congenital corneal epithelial stem cell deficiency (such as Stevens-Johnson syndrome, ocular cicatricial pemphigoid, graft-versus-host disease, and aniridia), recurrent pterygium, and idiopathic corneal epithelial stem cell deficiency.